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Abstract
Intellectual Disability (ID) is one of the most common neurodevelopmen-
tal disorders, affecting between 1.5-2% of individuals in the general popu-
lation. This pathology has a serious impact on the affected individuals,
their families and also on the health care system. Understanding the ge-
netic mechanisms implicated in the disease is challenging, since ID includes
a wide spectrum of possible underlying disorders and the genetic variants de-
termining the disease are highly heterogeneous, requiring the application of
different approaches and techniques, from cytogenetic analysis to the appli-
cation of most recent NGS strategies. In the last decades, big steps forward
have been done in the search of the genetics determinants for ID, however
today less then half of the patients receive a molecular diagnosis. Moreover,
the continue reporting of new ID-genes suggests that many of the genetic
variants causing ID still need to be discovered and understood. The aim of
the thesis is to identify new genes and genetic variants involved in ID, with
the use of diverse approaches and methodologies.
The first stage of the study has been the screening of a cohort of non-
syndromic ID patients with a gene-panel specific for non-syndromic ID. This
approach has led to the discover of 6 novel putative mutations and, when
possible, the impact of the variation has been evaluated in silico, with an
analysis of the protein structure. The screening also led to the selection of
two patients that underwent to whole-exome sequencing analysis with the
aim to identify the causative variant beyond the most common genes for the
disease. Notably, we have discovered 2 X-linked mutations having likely a
pathogenetic role. One is a missense mutation in CLCN4, a gene member
of the chloride channel family that only recently has been demonstrated to
cause ID. Another missense mutation has been found in ALG13 gene that
has been associated with X-linked non-syndromic ID only once but without
a clear explanation of its functioning.
The second part of the thesis concerns the investigation on genetic vari-
ants having a mild impact on the phenotype. We performed a Runs of
Homozygosity study to investigate the role of distant inbreeding in ID. The
analysis has revealed that the global amount of homozygosity and the num-
ber of homozygous stretches are associated with the degree of the impair-
ment. Finally, we also designed an association study for the Y chromosome
to investigate the presence of variants implicated in the development of cog-
nitive function in this genomic region. We analysed the general cognitive
function measured in 5 cross-sectional cohorts but did not find evidence for
an association on the Y chromosome.
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Sommario
La Disabilità Intellettiva (DI) è uno dei disturbi dello sviluppo più co-
muni, che colpisce circa il 1.5-2% della popolazione. Nella maggior parte dei
casi la patologia ha un impatto importante nella vita dei pazienti e delle loro
famiglie, e rappresenta anche una questione importante nella gestione della
salute pubblica. Capire i meccanismi genetici coinvolti in questo disturbo
è un problema complesso, poiché la DI è presente in un ampio spettro di
sindromi. Inoltre, le varianti causative sono molto eterogenee e richiedono
l’utilizzo di diversi approcci e tecnologie, dall’analisi citogenetica all’impiego
delle più recenti strategie di NGS. Nonostante i grandi passi in avanti com-
piuti nello studio delle sue cause genetiche, oggigiorno i pazienti che ricevono
una diagnosi molecolare sono meno della metà. Inoltre, la continua scoperta
di nuovi geni legati alla DI sta ad indicare che molte delle varianti genetiche
responsabili per la patologia devono ancora essere scoperte e approfondite.
Lo scopo della tesi è quello di identificare nuovi geni a varianti coinvolti
nell’insorgenza della DI, tramite l’utilizzo di diversi approcci e metodologie.
La prima parte dello studio è stato lo screening di una coorte di pazi-
enti con DI non sindromica utilizzando un pannello di geni specifico per
tale disturbo. Questo approccio ha consentito di scoprire 6 nuove mutazioni
candidate e, nei casi in cui è stato possibile, l’impatto delle variazioni è stato
valutato in silico con un’analisi della struttura delle proteine. Tale screening
ha anche permesso di selezionare due pazienti che sono stati analizzati con
whole-exome sequencing per la ricerca delle varianti causative al di fuori
dei geni più comuni per la patologia. In particolare, abbiamo scoperto la
presenza di due mutazioni X-linked probabilmente patogenetiche. La prima
è una mutazione missenso in CLCN4, un gene della famiglia dei canali del
cloro che solo molto recentemente è stato dimostrato causare DI. Un’altra
mutazione missenso è stata poi identificata nel gene ALG13, che è stato asso-
ciato una sola volta alla DI non sindromica ma senza una chiara spiegazione
del suo funzionamento.
La seconda parte della tesi riguarda la ricerca di varianti genetiche aventi
un effetto meno evidente sul fenotipo. Abbiamo svolto un’analisi delle aree
di omozigosità per indagare il ruolo dell’inbreeding nella DI. L’analisi ha
rivelato che la quantità globale di omozigosi ed il numero di segmenti sono
associati alla severità del deficit cognitivo. Infine, abbiamo realizzato uno
studio di associazione per il cromosoma Y allo scopo di indagare la pre-
senza di varianti coinvolte nello sviluppo della funzione cognitiva in questa
regione genomica. Abbiamo analizzato la funzione cognitiva generalizzata
in 5 coorti, senza però rilevare associazioni sul cromosoma Y.
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Chapter 1
General Introduction
This PhD thesis in an investigation on the genetic determinants in intellec-
tual disability. This introductory chapter is aimed to give an overview on
the main characteristics of the disease, the current knowledge of its genetic
causes and the purposes of our study.
1.1 Characteristics of Intellectual Disability
In accordance to the Diagnostic and Statistical Manual of Mental Disorders
5 (DSM-5), Intellectual Disability (ID) is an existential condition where a
cognitive ability below the average has an impact on intellectual and adap-
tive functioning. It involves limitations in conceptual skills, like language,
reasoning and memory but also impaired social relationships and deficits in
individual self-management and personal care. Because of the scarce use
of standardised assessment tools in the diagnosis and the presence of differ-
ences across populations and countries, epidemiological data on ID has been
always challenging to obtain. Epidemiological studies found that ID affects
between 1.5 - 2% in the Western populations [1]. This makes ID one the
most common neurodevelopmental disorder and one of the most important
unsolved issues in health care.
According to the DSM-5, the diagnosis of ID requires three criteria:
Deficits in intellectual functions such as reasoning, problem-solving, plan-
ning, abstract thinking, judgment, academic learning and learning
from experience, practical understanding, confirmed by both clinical
assessment and standardised intelligence testing. Intelligence Quotient
(IQ) is the most common parameter used to assess cognitive functions.
ID is characterised by a significantly lower IQ level compared to the
population mean (two standard deviations), corresponding to a score
of 70-75.
Deficits in adaptive functioning that result in failure to meet develop-
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mental and sociocultural standards for personal independence and so-
cial responsibility. Without ongoing support, adaptive deficits limit
the subject in one or more activities of daily life, such as communica-
tion, social participation, and independent living, and across multiple
environments, such as home, school, work, and recreation. A common
parameter for the evaluation of the adaptive functioning is the amount
of assistant teaching required at school.
Paediatric onset In order to distinguish ID from dementia, intellectual
and adaptive deficits must onset during the developmental period, i.e.
by 18 years of age.
Intellectual functions are evaluated with an overall measure of intel-
ligence usually referred as Intelligence Quotient (IQ). There are different
type of standardised and age-dependent tests available for clinicians to es-
timate IQ. Wechsler Intelligence Scale for Children-fourth edition (WISC-
IV) is probably the most common battery of tests being used. It offers two
main measures: the Full Scale Intelligence Quotient (FSIQ), which is a four-
domain test to assess the functioning of verbal comprehension, perceptual
reasoning, processing speed, and working memory; and the General Abilities
Index (GAI), calculated from verbal comprehension and perceptual reason-
ing scores, which is aimed to provide an estimate of overall reasoning ability
that is less influenced by working memory and processing speed. For chil-
dren aged less then four years old, scales for the assessment of Development
Quotient (DV) are usually preferred instead of measures of IQ. Evaluation of
DV is obtained with batteries of tests focused on motor abilities to evaluate
the acquisition of developmental milestone (walking, talking, smiling, track
objects with eyes) instead of cognitive or verbal skills. The most common
are the Bailey scales, Griffiths scale and the Brunet-Lezine scale (focused on
psychomotor development).
In the DSM-5, four severity levels are reported for ID (see Table 1.1) that
were established considering not only the degree of the impairment (i.e. IQ
scores) but also the amount and type of intervention needed. Mild category
includes individuals able to learn communicative and practical life skills but
slower than typical in all developmental areas. Basic self-management tasks
are usually achieved and assistance is only sporadically required. People
with moderate ID have noticeable speech and motor skills delays. Since
communication is not extended on complex levels and only basic personal
care tasks are carried out, they might need instruction and support in social
relationships due to the poor understanding of social conventions. Individ-
uals that fall into the severe category can only communicate on the most
basic levels and can not perform all self-care activities independently, thus
daily supervision and support is required. Frequently, people in this cate-
gory have sensorial disablements and physical limitations. Profound ID is
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Level QI range Proportion Support
Mild 50-55 70-75 85% Sporadic
Moderate 30-40 50-55 10% Limited
Severe 20-25 35-40 3-4% Extensive
Profound 0 20-25 1-2% Pervasive
Table 1.1: Degree of cognitive deficit in ID. Cognitive impairment is classified in four
levels: mild, moderate, severe and profound. For each level the corresponding IQ range,
the proportion among all ID cases and the required support for the patients are reported.
the most severe form of ID. Individuals are not capable of independent living
since there are significant developmental delays in all areas. Communication
is usually restricted to basic form of non-verbal communication and mobility
is often limited. The condition require close supervision.
In addition to the classification based on the degree of impairment, ID
can also be grouped into syndromic intellectual disability (Syn-ID) and non-
syndromic intellectual disability (NSyn-ID). In the syndromic form, ID is
present along with one or multiple clinical features or co-morbities. In some
cases, ID could be considered one of the several symptoms in well defined
syndromes (i.g. trisomy 21, fragile X syndrome, Prader-Willi syndrome,
Angelman syndrome). The range of clinical features that could manifest in
Syn-ID is broad (see Table 1.2): from visible anomalies as facial dysmor-
phisms and bone malformations, hearing or visual impairment, to more sub-
tle malformations in the brain and other apparatuses. There could be also
an extended range of neurological defects, as in the muscle tone, strength
and coordination, presence of seizures.
NSyn-ID is instead delineated by the only presence of ID as clinical fea-
ture. Despite the simple definition, the diagnosis of NSyn-ID is often chal-
lenging for clinicians since the more subtle anomalies and symptoms could
be extremely difficult to detect. Therefore, although this distinction is very
useful for clinical purposes, it should be considered that in some cases the
boundaries between Syn-ID and NSyn-IS are vague.
ID is an extremely heterogeneous condition that may result from neu-
rological factors (organic) or psycho-social factors (cultural/familiar), or a
combination of both that overall affects cognitive functioning. As regards
biological determinants, there are some environmental factors well known to
contribute to ID which include maternal intoxication (e.g. alcohol, drugs),
prematurity, malnutrition and infectious diseases during pregnancy, prema-
ture birth, perinatal anoxia, and trauma. The proportion of ID cases with
genetic base varies: for mild-moderate ID the genetic causes account for
25-50% of the cases, but they could reach the 85% of cases for more severe
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Anthropometric
disproportionate short/tall stature, micro/macrocephaly,
obesity
Dysmorphological
face, ears, hands, feet
Morphological
malformations in brain, bones, heart, gastrointestinal ap-
paratus, liver, spleen, kidneys, urogenital apparatus
Sensorial
sensorineural hearing loss, visual impairment (refractive er-
rors, strabismus, amblyopia, cortical blindness)
Neurological
seizures, hypotonia, spasticity, ataxia, dystonia
Endocrinological
hormone alterations
Table 1.2: List of the most common areas for syndromic features in ID.
forms. Despite the large diagnostic studies recently undertaken, the aetiol-
ogy remains unknown for about 50% of the cases and this proportion is even
higher for mild and borderline forms [2].
As regards ID prevalence, there is a well-known predominance of men
with ID. There is indeed an excess of males over females ranging from 30%
(for milder forms of ID) to 50% (for more severe forms). The male bias
and the evidence for X-linked transmission in large pedigrees studies led
researchers to investigate the role of X chromosome, finding a large number
of genes fundamental for the development of cognitive function and thus in-
volved in ID. One of the first syndromes identified as X-linked was the fragile
X syndrome, a condition characterised by ID and very distinctive clinical
features (elongated face, large ears, macroorchidism, stereotypic movements
and social anxiety), which is due to defects in FMR1 gene and represents the
most common cause of X-linked ID (XL-ID) (1-2% of all ID cases [3], 25%
of XL-ID cases [4]). Ever since, XL-ID has received much attention and
several studies have confirmed that X-linked gene defects have important
roles in the aetiology of ID and not only for men. For example, MECP2
is another well-known XL-ID gene causing the Rett syndrome, a neurode-
velopment disorder that affects almost exclusively females. XL-ID could be
both syndromic and isolated, but nonsyndromic XL-ID appears to be twice
as common as syndromic XL-ID: according to Piton et al. [3], of the over
100 genes identified in XL-ID, half of them are thought to cause NSyn-ID.
Despite men are 1.4 fold more likely to be affected by ID, recent studies
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suggest that the cumulative frequency of the detected X-linked pathogenetic
variants does not exceed 10%. Such discrepancy suggests that several genes
or loci on the X-chromosome involved in ID are yet to be identified. How-
ever Ropers et al. [4] hypotheses that the higher prevalence of ID and
other neurodevelopmental disorders (such as autism, Tourette’s syndrome)
in males could be due to diverse factors, from hormonal effects to defects
in gene-dosage in the two sexes (there are several genes that escape from
X-inactivation having no homologue on Y chromosome). Y-chromosomal
variants could be also implicated in the sex imbalance, an hypothesis arisen
after the discover of the male-specific effect of SRY gene on the brain func-
tion.
1.2 Genetic basis of Intellectual Disability
Given the broad spectrum of possible ID phenotypes, it is not surprising
that its genetics is highly complex. At present, 700 genes have now been
associated to ID [5]. Encoded proteins are diverse and can be involved in one
or more shared pathways or functional subclasses, taking part in complex
interaction networks. The etiopathogenesis encompasses so many different
genetic entities, varying from large chromosomal anomalies or copy number
variants (CNVs), to point mutations in single genes, requiring a wide-range
of diagnostic tools.
Biological processes altered in ID
Genes implicated in ID encode for diverse functional subclasses of proteins
and, until recently, their function has remained unclear in most cases. Ac-
cording to recent reviews [2, 5], the physiopathological mechanisms of ID
genes can be grouped in 4 major groups of cellular processes: neurogenesis,
neuronal migration, synaptic function and regulation of transcription and
translation.
Genes required for neurogenesis and the correct generation of neurons
from neural progenitor in the cortical zone. The molecular mechanisms
that control this neurogenesis process have not been fully understood,
but it is clear that a huge number of neurons is required for the correct
development of the human brain and abnormal neuron number could
result in disease. In some form of microcephaly, the reduced brain
size may be partially explained by the role of genes in inhibiting the
proliferation of neuronal progenitors. This is the case of ASPM, which
is a crucial gene for maintaining a symmetric, proliferative division of
neuroepithelial cells during brain development.
Genes required for neuronal migration implicated in the regulation of
the migration of newly born post-mitotic neurons. These genes mainly
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code for proteins involved in the function of the cytoskeleton, but also
cell division processes and axon/dendrite formation. Some forms of
lissencephaly (brain malformation resulting in a lack of development of
brain folds) are known to be caused by abnormal neuronal migration.
Histological studies revealed that the affected cortex presents layers
with different cell density, suggesting that many, perhaps late-born,
neurons have started but not completed the migration. PAFAH1B1
is a gene located in chromosome 17 and it is the main responsible
for lissencephaly cases. Defects in PAFAH1B1 cause delayed neuronal
migration and consequently decreased brain size and distorted cellular
organization in the ventricular zone.
Genes required for cellular processes involved in synaptic functions
as synaptogenesis and synaptic activities, but also synaptic plasticity,
especially in postnatal stage, during learning and acquisition of intel-
lectual performances. One of the most interesting is FMRP, a reg-
ulator of activity-dependent translation of mRNA-encoding proteins
involved in actin/microtubule-dependent synapse growth, remodelling
and function. The absence of FMRP causes fragile X syndrome: the
most common monogenic cause of ID with no major apparent specific
developmental brain anomaly.
Genes involved in transcription and translations encoding transcrip-
tion factors and cofactors, partners of signal transduction networks,
as well as chromatin-remodeling proteins. One of the most studied
is the RAS-MAPK pathway and the defects in its members like NF1,
whose encoded protein has the capacity to regulate several intracellular
processes. Mutations in this pathway impede the correct functioning
of the MAPK signalling cascade, a metabolic pathway that regulates
growth factors and embryological development and is associated with
a particular set of intellectual disabilities, the so-called RASopathies.
Given the fundamental role of the cellular processes regulated in the
pathway, RASopathies are usually syndromic forms of ID.
Understanding the biological processes and the genetic networks under-
lying ID genes is usually very challenging, since there is little information
about the gene functions and only a part of the genes involved has been
discovered. A new approach has been developed in this context, which
is focused on the analysis of shared molecular pathways for ID and other
neurodevelopmental disorders. It is well-known that there is a high co-
morbidity observed between neuropsychiatric disorders such as ID, autism,
schizophrenia and epilepsy, thus suggesting a possible shared genetic base.
Very recently Li et al. [7] have provided new insights into this field. Authors
carried out an analysis on the prevalence of de novo mutations, in particular
deleterious mutations, among these disorders and found shared biological
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process and non-coding regulatory elements of candidate genes, but also a
remarkable number of candidate genes associated with more than one dis-
order. SCN2A, a sodium channel gene, was found frequently affected across
all four disorders.
Genetic heterogeneity of ID and diagnostic approaches
Different criteria could be considered to classify the broad range of genetic
defects causing ID. Here we chose to give an overview based on the size of
the anomaly, from the extended chromosomal abnormalities to the single-
nucleotide deleterious variations, with an eye on the diagnostic approach
and the different stages of the typical genetic screening for ID.
Chromosomal anomalies
Chromosomal anomalies, for which diagnosis started under the microscope
and is currently performed with cytogenetic techniques, have been extend-
edly studied since decades and they still represent the most common known
cause of ID. Despite widespread prenatal diagnosis, Down syndrome (tri-
somy 21) remains the most important single cause of ID ( 6-8% [5]). Other
Figure 1.1: Chromosome rearrangements (source: Weckselbatt et al. [8]). (A)
Two non homologous chromosomes. (B) Simple intrachromosomal rearrangements. Black
arches indicate breakpoint junctions. (C) Interchromosomal rearrangements between two
different chromosome ends. Balanced translocations are copy-neutral and do not cause
a phenotype unless they disrupt developmentally important genes at breakpoints. While
unbalanced translocation (represented in the figure with two copies for each chromosome),
which usually occurs when one of the parents carries a balanced translocation and trans-
mits a normal copy and a translocated copy to the offspring, results in a partial monosomy
(segment E) and partial trisomy (segments B,C)
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chromosomal and structural aberrations are far less common, but taken to-
gether, they account for 15% of all cases [6]. Modifications could involve
deletions, duplications, inversions in a single chromosome (intrachromoso-
mal rearrangements), but they could also result in more complex structural
variations involving more then one chromosome (interchromosomal translo-
cations). Unbalanced translocations are particularly dangerous since they
lead to a partial trisomy and a partial monosomy in the two chromosomes
involved, as illustrated in Figure 1.1. The severity of the phenotype highly
depends on the genes included in the translocated regions, as for the other
structural variations after all. Uniparental disomy (UPD) occurs when the
child receives two alleles from the same parent. Such anomaly can result in
disease if the genomic segment involved contains recessive deleterious vari-
ants or when it encloses imprinted genes, in which either the maternal or
the paternal allele copy is silenced. This is the case of Prader-Willi and
Angelman that are both caused by imprint defects on chromosome 15.
One of the most common cytogenetic examinations is the banded karyo-
gram, which produces a visible karyotype for the detection of aneuploi-
dies and a series of lightly and darkly stained bands used as reference for
the identification of chromosomal rearrangements. Subtelomeric rearrange-
ments, i.e. deletions or duplications in the telomere-associated repeat region
due to imperfect meiotic recombination, are another common cause of ID (
may account for 5 - 7% of syndromic forms of ID ). Such structural variants
are more subtle to detect, thus usually multiprobe FISH analysis is applied,
in which fluorescently-labeled telomere-specific probes are hybridised to ge-
nomic DNA.
Copy number variations
Copy Number Variations (CNVs) are genomic stratches that occur with a
different number of copies compared to a reference genome assembly, arising
as either deletions or duplications. With the increasing availability genome-
wide microarrays, CNVs were discovered to contribute significantly to com-
mon genetic variation, covering approximately 12% of the entire genome in
the normal population. Array Comparative Genomic Hybridization (aCGH)
is a modification of the FISH technique in which probes have been optimised
for the use in a genome-wide microarray and it is currently widely applied.
Patients’ DNA and a reference DNA compete to attach (hybridise) on the
array and any alteration in copy number becomes visible as changes in the
fluorescent signal intensity, thus aCGH has been proven to be a specific, sen-
sitive and highthroughput technique for the detection of interstitial micro
deletions and duplications. High-density SNP array is also used for CNVs
detection, based on the analysis of the fluorescent intensity signals of probes.
As reported in Figure 1.2, the total signal intensity (called log R Ratio in
Illumina platforms) and allelic intensity ratio (B Allele Frequency) is con-
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Figure 1.2: Signal intensity analysis for CNV detection (source: Weckselbatt et
al. [8]). Log R ratio is the total florescent intensity signal, while B Allele Freq represent
the ratio between the two alleles. The figure illustrates the case of an insertion. Copy-
neutral segments A and C have 3 clusters in B allele frequency, corresponding to genotypes
BB, AB and AA. Compared to A and C, segment B presents an increased Log R ratio
and also a different pattern in the B allele frequency, corresponding to the genotypes of
an duplication (BBB, BBA, BAA, AAA).
sidered at each SNP marker. Such information, together with additional
parameters as inter-SNP distance and familiar relationships, is included in
Bayesian framework for the prediction of deletions and duplications. The
sensibility in terms of segment length of this methodology clearly depends
on the resolution and the density of the markers.
CNVs have been associated with several neuro-psychiatric diseases as
autism, schizophrenia, epilepsy and in particular ID. In some cases pathogenic-
ity is clear, when the CNV disrupts well known ID genes and compromises
their functioning, or when encompassing dosage-sensitive genes for which an
unusual number of copies could have harmful effects, even if the encoded
protein is preserved. It is estimated that CNVs, as a group, are responsi-
ble for 10-15% of all ID cases. However, there are copy number variants
for which a clinical interpretation is extremely difficult since considerable
variation in expressivity is observed.
Recent studies have detected a CNV enrichment for ID patients com-
pared to the general population but disease association remains unclear due
to the rarity of such variations which force researchers to carry studies on
very large sample sizes [9]. Moreover, deletions/insertions often contain
several genes whose role need to be interpreted. Great attention has been
given to de novo CNVs that were found to occur in the germline of 10%
of patients. One of the first studies in this context was conducted by Wa-
genstaller et al. [10], where a cohort of 67 ID children with unexplained
ID and normal karyotypes were examined with SNP-array data and several
de novo deletions and duplications were identified most likely as causative.
Interestingly, examining the size distribution of CNVs in the context of the
syndromic features, Cooper et al. [9] have found larger CNVs (400Kb) in
more severe developmental phenotypes associated with multiple congenital
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abnormalities (as craniofacial and cardiovascular defects) compared to chil-
dren with autism spectrum disorder. Thess results suggests a major effect
of large CNVs in the variation of more severe phenotypes .
Therefore, while their disease risk in general is well established (with an
odds ratio >20 for carriers of CNVs larger than 1.5 Mb [9]), the patholog-
ical consequences for most CNVs are not well characterised and additional
studies for the genomic mapping of these effects are required.
Dysfunction of single genes
As for other Mendelian disorders, genotyping data has been used in linkage
studies to investigate the cause of ID in large affected families [3]. However,
in the search for the causative gene in large consanguineous families, great
attention has been given to the detection of genomic area of homozygosity,
which appears as long sequences of homozygous SNPs. Stretches of ho-
mozygosity are interesting candidate regions in case of suspected recessive
inheritance, since the causative genetic defect is supposed to be included in
autozygosity areas. This approach, known as homozygosity mapping, led
researchers to move the focus on autosomal recessive variants involved in
ID. Investigation carried out in large consanguineous families led to the dis-
cover of several autosomal ID genes [11, 12] and encouraged researchers to
speculate an important part played by autosomal variants in the high rate
of unexplained IDs.
Homozygosity mapping and other candidate gene studies have been con-
ducted since decades with an increasing diagnostic yield over time, also due
to the refinement provided by microarray studies, but the power in mutation
detection has dramatically boosted with the introduction of next-generation
sequencing (NGS), especially for sporadic ID. Direct sequencing and screen-
ing of candidate genes are now being replaced in diagnostic pipelines by more
high-throughput sequencing technologies, as multiplex targeted sequencing
of a few genes in large cohorts, selective targeted sequencing of up to several
hundred genes, whole-exome sequencing (WES) and whole-genome sequenc-
ing (WGS).
The use of NGS strategies is particularly challenging in the case of ID,
which presents great phenotype variation among patients and could involve
a large range of gene and biological processes. For some clinically well-
defined but very rare syndromes, exome sequencing of a small number of
unrelated patients with a genotype-phenotype correlation analysis has been
shown to be an efficient approach. The development of a strategy for the
prioritisation of detected variants, based on overlapping clinical features in
affected patients, made possible the discover of the genetic cause of some
rare mendelian disorders [13]. The reverse approach is also widely used, in
which variants are prioritised with computational methods based on their
potential functional significance, pathway information and protein-protein
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interactions [14, 15].
In case of sporadic ID, with no possibility for an analysis of overlap-
ping mutations or clinical feature in multiple patients, trios-base sequencing
studies are often performed. This approach involves the examination of the
patient together with his unaffected parents. Segregation analysis is a pow-
erful strategy to filter out detected variants when searching for the putative
mutation. In 2010 Vissers et al. [16] performed family based WES ap-
proach in 10 patients with severe ID and unknown cause, and found de novo
mutations likely to be pathogenic in six individuals. This and other simi-
lar findings led the investigators to believe that de novo mutations play an
important role in the aetiology of ID, especially for more severe forms, pro-
viding also a possible explanation for the relatively high frequence of severe
early-onset neuropsychiatric disorders in outbred populations. A de novo
paradigm for ID has been very recently confirmed by a large-scale whole-
genome sequencing study on 50 patients with severe ID, in which WGS was
applied after an extensive genetic prescreening, including exome sequencing
analysis [17]. Authors found a global enrichment of loss-of-function de novo
mutations compared to previously published rates and also that de novo
mutations occurred with higher frequency in genes previously implicated in
ID-related disorders. Moreover, of the 21 patients with pathogenetic variant
identified, 20 of them showed de novo events, including single-nucleotide
variations, CNVs or structural variants, confirming that de novo variants
are a major cause of sporadic forms of ID.
Another interesting result of the study regards the diagnostic yield of
sequencing approaches, summarised in Figure 1.3. Before WGS analysis,
patients underwent an extensive clinical and genetic examination, including
targeted gene, SNP array and WES analysis, without obtaining a molec-
ular diagnosis. Based on the diagnostic rates of the previous steps in the
screening, the cumulative estimate for WGS to reach a conclusive genetic
diagnosis was 62%. Despite the non-coding part of the genome was included
in the analysis, all 78 mutations identified by WGS were found in the coding
region but interestingly 65 of them were missed or detected with too low
coverage in WES.
In the past 5 years NGS technologies have become more affordable in
terms of costs, appearing as a very attractive strategy in the field of genetic
diagnosis. However new challenges have emerged, as the interpretation of
the big amount of data generated by NGS. Moreover, the recent findings of
the Encyclopedia of DNA Elements (ENCODE) consortium have introduced
new questions about the role of non-coding variants. The ENCODE project
has identified gene-specific enhancer and repressor elements throughout the
non-coding part of the genome (98.5%) which was referred to as junk DNA
in the past. These findings suggest that non-coding CNVs may be good
targets for investigation on ID since they could have disruptive effect on the
regulatory landscape of the genome and result in disease [5].
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Figure 1.3: Diagnostic yield in patients with severe ID per technology in Glissen
et al. study (source: Glissen et al. [17]) . The three charts summarise the diagnostic
yield of a genetic screening on a 1500 cohort of severe ID patients. Brackets indicate the
group of patients with no causative variant identified and subsequently analysed in the
next step of the screening. The proportion of subjects diagnosed with microarrays analysis
was 12%, for the others WES analysis led to a molecular diagnosis in 27% of cases. The
remaning subjects were then analysed with WGS and genetic cause was identified in 62%
of cases.
1.3 Aim of the thesis and contents
Despite the great steps forward in the understanding of genetic mechanisms
underlying ID, the majority of the patients remain still without a molecular
diagnosis, thus additional efforts are required. ID is one of the most serious
neurodevelopmental disorders, which has a serious impact not only on the
affected individuals and their families but also on the health care system
and society. The research for the genetic determinants in ID is a complex
problem, due to diverse factors. The spectrum of possible underlying disor-
ders is extensive, requiring an ample range of clinical investigations for its
determination. Then one side, the high heterogeneity of the pathology impli-
cates that researchers are required to apply very different approaches in the
analysis, from cytogenetic techniques to the application of most recent NGS
strategies. On the other side, the continue reporting on new genes/genetic
variants implicated in ID in the scientific community suggests that there is
a lot in the genetics of ID that still need to be discovered and understood.
In this context, we set up a study aimed to identify new genes and
genetic variants involved in ID and tried to approach the complexity of the
pathology employing diverse methodologies. The first stage of the study has
been the screening of a cohort of non-syndromic ID patients for mutations
in genes already known to be associated to the disease, that is described in
Chapter 1. Thanks to the design of a gene-panel specific for NSyn-ID that
has been implemented in NGS technology, we were able to identify 6 novel
mutations likely involved in the disease. The importance of this screening
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has been not only the discover of novel variations, but also the forming of a
sub-cohort of NSyn-ID patients not carrying pathogenetic mutations in the
most common genes for the disease. In this way we had higher chances for
finding defects in genes and genomic regions not associated with NSyn-ID
yet. Two of these patients were selected and analysed with whole-exome
sequencing. The analysis is described in Chapter 2. Thanks to a trio-
based approach, we were able to perform an accurate selection among the
43K variants detected and identify two plausible candidates for having a
pathogenetic role. One of those variants occurred in gene CLCN4 that only
very recently has been associated specifically to ID. The other variant is
included in the ALG13 gene that was only hypothesised to be involved in
NSyn-ID in one previous investigation.
The second part of this manuscript concerns the investigation on genetic
variants having a milder effect on the phenotype. In Chapter 3 we investigate
the role of Runs of Homozygosity in ID. Contrary to our first hypothesis, we
did not find an excess of homozygosity in syndromic ID patients compared to
non-syndromic cases. However, our analysis revealed that the global amount
of homozygosity and number of homozygous stretches are associated with
the degree of the impairment. Indeed, despite not being the cause of the
disease, the presence ROHs seems to modulate the severity of the cognitive
impairment.
In the search of genetic variants having an influence on the ID pheno-
type, we also considered a genomic region that has been almost completely
neglected in the past that is the Y chromosome. As the investigation in
neurodevelopmental disorders has recently turned the focus on this region
and obtained interesting results, especially for autism, we designed an asso-
ciation study for the Y chromosome that can potentially give new insights in
the genetics of ID. In Chapter 4 we describe the implementation of a single-
SNP approach for the Y chromosome and present the results of the analysis
for the general cognitive function in 5 cross-sectional cohorts. No evidence
for a role of Y chromosome variants in cognitive function has been found
but the study could represent an important starting point for improving the
knowledge of this genomic region.
1.4 Patient recruitment
A cohorts of 668 affected children have been founded specifically for the
project. This was possible thanks to the collaboration of the paediatric
clinics of 4 Italian hospitals which the patients were sampled from: IRCCS-
Burlo Garofolo (Trieste), IRCCS-Casa Sollievo della Sofferenza (Foggia),
Città della Scienza e della Salute (Torino), IRCCS-Oasi Maria SS. (Enna),
which are specialised ID Health Services for patients coming from the whole
Italian territory (Figure 1.4).
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Figure 1.4: Recruitment of ID-patients. Affected children have been recruited in 4
Italian hospitals. For each centre, the number of subjects is reported.
In each centre, probands have been clinically evaluated. A diagnostic
algorithm has been applied to exclude cases of non-genetic ID and distin-
guish between syndromic and non-syndromic ID, depending on the results of
clinical evaluations. Since part of the study has been focused specifically on
the Nsyn-ID, great deal of effort has been put for the detection of syndromic
features in all areas (Table 1.3). Neurodevelopmental assessment has been
collected using developmental scales (Bayley III, Brunet-Lezine, Griffiths)
or intelligence scale (Weschler), according to the age of the patients.
Thanks to the fruitful collaboration between the groups and agreed cri-
teria for the clinical and genetic evaluations, we were able to obtain a large
cohort of ID patients that have been the focus of most stages of the project.
The gene-panel screening and the WES study was carried out on the sub-
cohorts of NSyn-ID patients, while the homozygosity study involved all sub-
jects.
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EXAMINATIONS EXCLUSION CRITERIA
ANAMNESIS
Pre-/peri-/neonatal history Adverse events
SPECIALIST EVALUATIONS
Orthopaedic Bone malformations
ENT Sensorineural hearing loss
Ophthalmological Severe refraction disease, fundusalterations
Endocrinological Hormones alterations, urogenitalmalformations
Dysmorphological and
anthropometric
Major dysmorphisms,
micro/macrosomia
INSTRUMENTAL EVALUATION
Brain MRI Major malformations
Echocardiography Heart malformations
Abdominal ultrasound Gastrointestinal, hepatic, splenic,renal malformations
EEG Seizures or EEG alterations
Table 1.3: List of clinical examinations and exclusion criteria for the diagnosis
of non-syndromic ID.
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Chapter 2
Target sequencing approach
for non-syndromic
Intellectual Disability
In this chapter we present a study on non-syndromic ID that has revealed 6
novel candidate mutations. The work has been published in Mutation Re-
search as Morgan A. et al “Target sequencing approach intended to discover
new mutations in non-syndromic intellectual disability”. Mutat Res. 2015
Nov;781:32-6. Contributors for this work are reported at the end of the
chapter.
2.1 The genetic heterogeneity of Nsyn-ID
Most of the new insights on the genetics of ID emerged over the last years
has been acquired thanks to studies focused on syndromic ID, which is the
most common forms of ID.
Non-syndromic intellectual disability (NSyn-ID), characterised by cogni-
tive impairment as the unique clinical feature, has been poorly investigated.
Understanding the genetics behind NSyn-ID would be relevant both for pa-
tients care and for exploring the basic mechanisms underlying the human
cognition and intellect. In fact genes whose alteration causes NSyn-ID could
be likely involved in the learning and memory processes. Moreover, NSyn-
ID shares some genetic mechanisms with the group of neurodevelopmental
disorders known as Autism Spectrum Disorder [18]. In this perspective,
NSyn-ID represents a relevant health care issue, which demands undeniable
investigator efforts.
Targeted sequencing (TS) allows the sequencing of a selected number
of genes in a multi-sample plate and offers several advantages. A coverage
with high depth and a smaller portion of poorly covered regions ensure a
high sensitivity and specificity for the detection of pathogenic events in the
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regions of interest. Indeed, the actual coverage with the exome or whole-
genome strategies is still frequently insufficient, which may result in missing
mutations. Moreover, TS allows the simultaneous analysis of a high number
of patients with significantly lower costs, not only in terms of the technol-
ogy per se but especially of data analysis, storage and interpretation, when
compared to WES.
Quite surprisingly, when the project was started, we could not find in lit-
erature a comprehensive list of genes involved in non-syndromic ID. There-
fore a preliminary step of the study was the selection of genes related to
Nsyn-ID that led to the compilation of a 71 genes list (see Table 2.1). In
this context, we considered non-syndromic ID genes all genes that have been
implicated at least once in Nsyn-ID. This means that genes could have been
also associated to syndromic forms of ID.
With the multiple goals to (a) confirm the involvement of known genes,
(b) find novel mutations in NSyn-ID-genes and (c) assess TS as NSyn-ID
diagnostic tool, we analyzed 65 NSyn-ID patients with a 71 genes-panel.
2.2 Targeted sequencing study
We collected clinical information, peripheral blood gDNA samples and in-
formed consent from 65 NSyn-ID patients (43 patients with their parents
and 22 isolated ones), already found negative to the pathogenic CNVs de-
tection via SNPs-array analysis. Our selected cohort of patients consists of
23 females and 42 males.
A specific Targeted Gene Panel has been defined by the Ion AmpliSe-
qTM Designer v1.2 tool (Life Technologies, CA, USA). 71 genes have been
selected on the basis of the most updated literature survey (up to 2013),
including all genes reported at least once as causative of NSyn-ID (Table
2.1). This selection includes 36 X-linked and 35 autosomal genes. Single-
end sequencing was carried out on the Ion Personal Genome Machine System
on Ion 318TM Chips (Life Technologies, CA, USA). The variants were an-
notated using the ANNOVAR software. CNVs analysis was performed by
Conifer (COpy Number Inference From Exome Reads) tool [19]. Whenever
needed, we manually investigated the raw sequence reads using the Integra-
tive Genomics Viewer (IGV) [20] to exclude false positives calls.
The sequencing process produced a mean of 102 Mega bases of raw se-
quence data per individual. An average of 88% of the targeted regions was
covered at least 20-fold. A mean depth of coverage of 227X and an average
of 133 variants for each individual were obtained.
Candidate causative variants have been selected with a filtering proce-
dure applied on the variants called for each proband based on two criteria:
1. variant frequency: common polymorphisms have been removed re-
ferring to 1000 Genomes Project (http://www.1000genomes.org/) and
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the NHLBI-ESP 6500 exome project (http://evs.gs.washington. edu/EVS/)
databases;
2. Mendelian consistency: only variants fitting one between de novo, X-
linked or recessive inheritance patterns have been included.
All the identified candidate disease-causing variants have been analysed
by direct Sanger sequencing on patients and parents.
2.3 Protein structure
In vivo functional studies are difficult to perform for mutated genes in ID pa-
tients since the affected tissue, the brain, cannot be easily accessed. There-
fore the impact of missense mutations on the protein function has been
assessed first using in silico pathogenicity predictors (Polyphen-2 [21], Mu-
tationTaster [22] and SIFT [23], PhyloP algorithm [25] for evolutionary con-
servation) and successively with Molecular Dynamics (MD) analysis. MD
simulations provide powerful tools to estimate how the variation affects the
protein structure, which is often a critical element of their function. In this
study, MD analysis has been performed by the prof. Pricl’s group at the
Chemical Sciences Department, University of Trieste, thanks to a fruitful
collaboration established for the project. Only the results of MD analysis
is given here and we refer the reader to the published article for a detailed
description of the protocol.
High-resolution crystallographic is used as starting geometry for both
wild-type and mutant proteins, then mutation is introduced in the protein
structure. Three-dimensional model structure of the full-length protein is
built by a combination of homology-based techniques. To this aim, three-
dimensional computational models of the proteins have been created for
those candidate genes having crystal structure available. After a prelimi-
nary screening of the Protein Data Bank (PDB) repository, either partially-
matching or significant homology templates have been identified as reliable
starting point for 3D protein homology modeling only for three of the pro-
teins involved: Atrx, Pqpb1 and Arid1b.
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Gene Chromosome Reference
ACSL4 X Nature Genet. 30: 436-440, 2002
AGTR2 X Hum Genet. 2004 Jan;114(2):211-3
AP1S2 X Am J Hum Genet. 2006 December; 79(6): 1119-1124
ARHGEF6 X Nature Genet. 26: 247-250, 2000
ARID1B 6 Am J Hum Genet. 2012 March 9; 90(3): 565-572
ARX X J Child Neurol. 2007 Jun;22(6):744-8
ATRX X Am J Med Genet. 2002 Jul 1;110(3):243-7
AUTS2 7 Hum Genet (2007) 121:501-509
C10orf11 10 Europ. J. Hum. Genet. 18: 291-295, 2010
CACNG2 22 Am J Hum Genet. 2011 Mar 11;88(3):306-16
CASK X Nature Genet. 41: 535-543, 2009
CC2D1A 19 J. Med. Genet. 40: 729-732, 2003
CDH15 16 Am. J. Hum. Genet. 83: 703-713, 2008
CDK5R1 17 Neurogenetics. 2006 Mar;7(1):59-66
CDKL3 5 Am J Med Genet A. 2008 May 15;146A(10):1267-79
CIC 19 Nat Genet. 2010 Dec;42(12):1109-12
CRBN 3 Neurology. 2004 Nov 23;63(10):1927-31
DLG3 X Neurogenetics. 2010 May;11(2):251-5
DOCK8 9 Genomics. 2008 Feb;91(2):195-202
DYNC1H1 14 Nat Genet. 2010 Dec;42(12):1109-12
EPB41L1 20 Am J Hum Genet. 2011 Mar 11;88(3):306-16. doi: 10.1016
FGD1 X Clin Genet. 2002 Feb;61(2):139-45
FOXP1 3 Am J Hum Genet. 2010 Nov 12;87(5):671-8
FTSJ1 X Am J Hum Genet. 2004 Aug;75(2):305-9
GDI1 X Am J Med Genet A. 2011 Dec;155A(12):3067-70
GPD2 2 Hum Genet. 2009 Jan;124(6):649-58
GRIA3 X Am J Med Genet A. 2004 Dec 1;131(2):174-8
GRIK2 6 Am J Hum Genet. 2007 Oct;81(4):792-8
GRIN1 9 Am J Hum Genet. 2011 Mar 11;88(3):306-16
GRIN2A 16 Nat Genet. 2010 Nov;42(11):1021-6
GRIN2B 12 Nat Genet. 2010 Nov;42(11):1021-6
HCFC1 X Am J Hum Genet. 2012 Oct 5;91(4):694-702a
HUWE1 X Am J Hum Genet. 2008 Feb;82(2):432-43
IL1RAPL1 X Am J Med Genet A. 2011 May;155A(5):1109-14
IQSEC2 X Nat Genet. 2010 Jun;42(6):486-8
KDM5C X Am J Hum Genet. 2005 Feb;76(2):227-36
KIAA2022 X Med Genet. 2004 October; 41(10): 736-742
KIRREL3 11 Am J Hum Genet. 2008 December 12; 83(6): 703-713
MAGT1 X Am. J. Hum. Genet. 82: 1150-1157, 2008
MBD5 2 Am. J. Hum. Genet. 81: 768-779, 2007
MECP2 X FEBS Lett. 2000 Sep 22;481(3):285-8
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Gene Chromosome Reference
MED23 6 Science. 2011 Aug 26;333(6046):1161-3
NLGN4 X Am J Hum Genet. 2004 Mar;74(3):552-7
NRXN1 2 Europ. J. Hum. Genet. 20: 1240-1247, 2012
NSUN2 5 Am J Hum Genet. 2012 May 4; 90(5): 856-863
OMG 17 Neurogenetics. 2006 Mar;7(1):59-66
PAK3 X Yi Chuan. 2007 May;29(5):523-7
PHF8 X Mol Cell. 2010 Apr 23;38(2):165-78
PQBP1 X Nat Genet. 2003 Dec;35(4):313-5
PRSS12 4 Am J Hum Genet. 2008 May;82(5):1158-64
PTCHD1 X Sci Transl Med. 2010 Sep 15;2(49):49ra68
RAB39B X Am J Med Genet. 2000 Oct 23;94(5):376-82
RPS6KA3 X Clin Genet. 2006 Dec;70(6):509-15
SETBP1 18 Eur J Med Genet. 2012 Mar;55(3):216-21
SHANK2 11 Nat Genet. 2010 Jun;42(6):489-91
SHANK3 22 Am J Hum Genet. 2011 Mar 11
SLC6A8 X Am J Hum Genet. 2004 Jul;75(1):97-105
STXBP1 9 Am J Hum Genet. 2011 Mar 11;88(3):306-16
SYNGAP1 6 New Eng. J. Med. 360: 599-605, 2009
SYP X Nat Genet. 41: 535-543, 2009
TCF4 18 Am. J. Med. Genet. 146A: 2053-2059, 2008
TECR 19 Hum Mol Genet. 2011 Apr 1;20(7):1285-9
TRAPPC9 8 Am J Hum Genet. 2009 Dec;85(6):909-15
TSPAN7 X J. Med. Genet. 39: 430-433, 2002
TUSC3 8 Am. J. Hum. Genet. 82: 1150-1157, 2008
UPF3B X Nature Genet. 39: 1127-1133, 2007
ZDHHC9 X Am. J. Hum. Genet. 80: 982-987, 2007
ZNF41 X Am J Hum Genet. 2003 Dec;73(6):1341-54
ZNF674 X Am J Hum Genet. 2006 Feb;78(2):265-78
ZNF711 X Nat Genet. 41: 535-543, 2009
ZNF81 X J. Med. Genet. 41: 394-399, 2004
Table 2.1: List of 71 Nsyn-ID genes. The panel includes 35 autosomal genes and 36
X chromosome genes.
2.4 Novel mutations detected for NSyn-ID
The analysis of 65 NSyn-ID patients (10 of them affected by severe ID) led to the
identification of 4 novel X-linked point mutations, located in DLG3, IL1RAPL1,
ATRX, and PQBP1 genes, as well as 2 novel de novo point mutations in autosomal
genes ARID1B and KIRREL3 (Table 2.2). De novo variants have been called in
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Figure 2.1: Protein structure of ATRX (source: Morgan A. et al 2015). (A)
Comparison of the equilibrated MD snapshots of the Atrx wt (dim gray) with D1781V
(orange) mutants and (B) the close-ups of the receptor binding site of ATP. The ligand
is shown as balls and sticks colored according to the respective protein complex. Hydro-
gen atoms, water molecules, ions, and counterions were omitted for the sake of clarity.
(C) General secondary structure description of the Atrx protein (amino acids 1547￿1802)
during MD simulations of the wt and D1781V. The y-axis gives the percentage of specific
secondary structure for each Atrx residue.
heterozygous state and it is assumed they have a dominant effect. Both genes
involved, ARID1B and KIRREL3, were previously reported associated to non-
syndromic ID [26, 27]. Moreover, we found a novel missense mutation in GRIN2A
gene predicted as highly pathogenic by all the prediction tools, although the absence
of parental DNA did not permit to study the mutation segregation. No small CNV
has been detected by the use of CONIFER.
We conducted an accurate patient clinical re-evaluation in order to detect any
phenotypic sign but all evaluated patients showed no additional findings, confirming
the previous clinical diagnosis of non-syndromic ID. Moreover, all mutations discov-
ered in the study have been never reported before, neither as rare polymorphism in
dbSNP nor as mutations in OMIM (Online Mendelian Inheritance in Man). These
facts clearly support their pathogenicity and the genetic and allelic heterogeneity
hypothesis behind the ID.
Thanks to the analysis of protein structure, the Atrx mutation was found to
be located in the helicase/ATPase domain at the carboxyl terminus of the protein
that includes a potential nucleotide-binding site for ATP constituted by residues
1594-1601. The MD simulations revealed an expansion of the ATP binding pocket
from an average dynamic volume (ADV) (Figure 2.1 A,B). A different secondary
structure rearrangement can be clearly observed (Figure 2.1 C). As a consequence,
ATP fits less tightly in the mutant protein binding pocket, in fact the binding free
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Figure 2.2: Protein structure of PQBP1 (source: Morgan A. et al 2015). (A)
Zoomed view of the superposition between two snapshots representing Pqbp1wt/U5, de-
picted pink/light gray respectively and Pqbp1 D102H/U5 complex in blue and cyan. (B)
RMSD of the coordinates of the backbone atoms of Pqbp1/U5 along the MD simulation.
Comparison of the equilibrated MD snapshots of the wt Pqbp1 protein (blue) with D102H
(pink) mutant in complex with U5.
energy (DGbind) for the wild- type/ATP Atrx complex is -17.45 ± 0.34 kcal/mol
while this value drops to -14.56 ± 0.32 kcal/mol in the case of the D1781V/ATP
variant assembly.
The Pqpb1 protein has two characteristic domains that preside over protein/protein
interactions, specifically with the WBP11 and U5-15kD proteins. MD simulations
of the wild-type/U5 and D102H mutant pqpb1/U5 protein/protein complexes re-
vealed that U5 interacts more loosely with the mutant protein than with the wild-
type counterpart (Figure 2.2 A,B). This effect can be quantitatively appreciated by
considering the root mean square deviation (RMSD) of U5 backbone atoms with
time shown in Figure 2.2.
Arid1b protein is involved in chromatin remodeling. The G1098E mutant pro-
tein activity was evaluated by performing MD simulations of their interaction with
an AT-rich DNA fragment. The substitution of a glycine with a charged and bulky
glutamic acid results in a substantial alteration of the interactions of the mutant
protein with the nucleic acid (Figure 2.3): in fact, the negatively charged side chain
of E1098 points directly toward the binding region, thereby interfering, via electro-
static and steric repulsions, with the negatively charged backbone of DNA.
In this study we analysed 43 trios and additional 22 isolated patients affected
by NSyn-ID, finding 6 (4 X-linked, 2 de novo) putative pathogenic mutations and
a potentially causative mutation in GRIN2A gene. The discovery rate is therefore
close to 11% in our cohort. These findings show that however a large portion
of our patients is negative to the screening. We focused our study on a specific
and strictly well-selected cohort of patients, affected by intellectual impairment
without any other relevant sings or symptoms. Unlike syndromic ID, NSyn-ID
seems therefore a truly complex phenotype, likely caused by a deep and broad
interaction between gene defects and environment. We would speculate that part
of the genetics behind NSyn-ID, particularly for the milder forms, could be related
genes not included in the panel or to genetic variants in regulative sequences, which
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Figure 2.3: Protein structure of ARID1B (source: Morgan A. et al 2015).
Zoomed in view of the interaction zone of DNA AT-rich sequence and Arid WT/G1098E,
in green and gold respectively. Hydrogen atoms, water molecules, ions and counterions
are not shown for clarity.
can not be detected with the TS approach. In addition, some environmental factors
could further modulate the genetic variants magnitude, contributing therefore to
arise the phenotype.
Consistently with the broad genetic heterogeneity behind the NSyn-ID, our TS
analysis showed a quite low discovery rate, pointing out that several other genes
remain still to be discovered; as matter of fact over the last year, several new NSyn-
ID genes have been identified [21,22]. Consequently, the discovery rate could be
surely improved over the time by a systematic genes list update.
In conclusion, our results represent an important contribution for future studies
on NSyn-ID aimed to eventually increase evidences on the role of known genes
or to discover new NSyn-ID genes. A better knowledge on NSyn-ID would be
essential to the understanding of the basic abilities in human cognition and intellect,
because genes involved in NSyn-ID are likely related to the learning and memory
processes and the perturbation of the related pathways could affect these processes,
as suggested by the GRIN2A involvement in neural plasticity [23].
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Chapter 3
Two patients with
unexplained non-syndromic
ID analysed with
Whole-Exome Sequencing
In this chapter the Whole-Exome Sequencing analysis of two NSyn-ID patients is
presented. Children were visited at the genetic clinic of Maternal-Child hospital
Burlo Garofolo (Trieste, IT). Contributors for this work are reported at the end of
the chapter.
3.1 Research of new genes for ID
Human brain development involves complex regulation of cellular proliferation, sig-
naling and transcription pathways, thus many relevant genes are expected to be
involved in Intellectual Disability. More then 700 ID-genes have now been identi-
fied that can be analysed for the molecular diagnosis, but a large number of new
genes are discovered every year. In the Intellectual Disability Gene Panel used at
the Dept. of Human Genetics of the Radboudumc, Nijmegen, the recognised ID
genes for 2014 amount to 15 (see Table 3.1). There is evidence for a large fraction
of ID genes that still remains to be discovered.
Whole-exome sequencing (WES) is the application of the next-generation tech-
nology to determine the variations of all coding regions. NGS has influenced all
fields of biological research but especially the investigation of disease-causing mu-
tations in Mendelian disorders, including those involving a large number of genes.
The study of Vissers et al. [16] has demonstrated the power of this approach: they
analysed ten individuals with unexplained ID and identified and validated non-
synonymous de novo mutations in nine genes. Certainly the current knowledge
and resources for understanding the non-coding variation is still limited, requiring
extensive functional follow-up to determine the role in disease, but it seems that
coding region variants plays the major role in the pathogenesis of ID.
There are no doubts about the power of approaches that allow investigators to
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Gene Inheritance Phenotype Reference
AHDC1 AD Xia-Gibbs syndrome Xia et al. 2014
FBXO31 AR Intellectual disability Mir et al. 2014
FMN2 AR Intellectual disability Law et al. 2014
HCN1 AD Infantile epilepticencephalopathy Nava et al. 2014
KPTN AR Intellectual disability Baple et al. 2014
METTL23 AR Intellectual disability Bernkopf et al. 2014
NFIA AD
Hypoplastic corpus
callosum, ventriculomegaly,
seizures and urinary tract
defect
Rao et al. 2014
PGAP1 AR Intellectual disability Murakami et al. 2014
PGAP3 AR
Hypoplastic corpus
callosum, ventriculomegaly,
seizures and urinary tract
defect
Howard et al. 2014
POGZ AD Autism, Intellectualdisability, schizophrenia Gilissen et al. 2014
PTDSS1 AD Lenz-Majewski hyperostoticdwarfism Sousa et al. 2014
SNX14 AR Spinocerebellar ataxia,Intellectual disability Sousa et al. 2014
SOX11 AD Intellectual disability Tsurusaki et al. 2014
USP9X XL-D Intellectual disability Homan et al. 2014
YAP1 AD
Coloboma, ocular, with or
without hearing
impairment, cleft lip/palate,
and/or Intellectual disability
Williamson et al. 2014
Table 3.1: New ID genes published in 2014 Gene list obtained from the Intellec-
tual Disability Gene Panel (v.DGD141114) used at the Dept. of Human Genetics of the
Radboudumc, Nijmegen, The Netherlands. Inheritance model codes are: AD=Autosomal
Dominant, AR=Autosomal Recessive, XL-D=X-linked Dominant. OMIM ID is referred
to the phenotype.
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research causative variants across all genome, but it comes also with big challenges,
mainly in the interpretation of the results. Notably, it is estimated that for each
individual WES data contain around 10.000 nonsynonymous variants depending
on ethnicity and calling methods [28]. The discrimination of the putative variants
is currently the most demanding part of the analysis and efficient strategies still
need to be developed to this aim. The most common approach is to analyse the
inheritance mode of the disease, and use in silico predictor to evaluate functional
and biological significance of each variant.
The 71-gene panel screening described in Chapter 2 led to the identification
of candidate causative variants in 6 NSyn-ID patients but also ensured with high
probability that the remaining individuals do not carry pathogenetic mutations in
the most common genes for NSyn-ID. With this precondition, we selected two af-
fected children among the ones resulted as negative in the gene panel screening and
set up a trio-based WES study aimed to reveal the genetic cause of the disease.
The analysis led to the identification of 3 X-linked candidate variants: one is lo-
cated in the GPR64 gene that according to the current knowledge of its function
is unlikely involved in ID; while other 2 variants, carried by one patient and his
affected brother, were found in CLCN4 and ALG13 genes, which can be realistically
implicated in the disease. However, this study does not amounts to a final step in
our project. These finding will require functional studies that, at the moment, are
the only way to demonstrate the pathogenicity of candidate mutations identified.
3.2 Whole-Exome sequencing study
Two families have been selected for the WES analysis. Among patients with no
molecular diagnosis after the Target Sequencing, two individuals have been chosen
and analysed together with their parents. Family F1 included an affected male child
12-781, father 12-779, mother 12-780. A non-syndromic ID of moderate level was
diagnosed in the boy. Family F2 included an affected male child 11-965, affected
brother 11-962, father 13-1537, mother 12-1536. ID showed variability among the
two brothers: in patient 11-965 a severe non-syndromic ID was diagnosed, while
patient 11-962 showed a syndromic form of ID, characterised by the presence of
seizures and a moderate cognitive deficit. Proband 11-965 and his parents were
included in the WES analysis whereas his brother has been analysed only for the
validation of candidate variants.
The WES was performed at the Europe Life Technologies Ion AmpliSeq Exome
Certified Service Providers, CRIBI Sequencing Core, University of Padua, Italy.
The DNA libraries were prepared employing the Ion AmpliSeq Exome Kit and
were then sequenced by the Ion Proton System (Life Technologies, CA, USA),
according to the standardised procedures. Reads mapping and variant calling were
performed by the Ion TorrentSuite v4.0 software (Life Technologies, CA, USA) set
up with standardised parameters. Single Nucleotide Variations (SNVs) and small
Insertions and Deletions (INDELs) were reported into a Variant Call Format (VCF)
version 4.1. SNVs and INDELS were annotated using the most updated version of
ANNOVA [29].
The major issue in WES analysis is to identify the candidate variants among the
several variations detected. To this aim, we set up an internal database accounting
for the overall recurrent variations called in the sequenced patients, affected by
diseases other than ID. In this way we were able to identify systematic errors,
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Figure 3.1: Custom bioin-
formatic pipeline for vari-
ant filtering. After annota-
tion, variant were removed if:
1) synonymous, 2) off-target,
3) having MAF>0.01, 4) sys-
tematic errors. For de novo
variants, additional filters have
been applied: frequency of the
alternative allele must be be-
tween 0.4 and 0.6 and the vari-
ant must be called on the dou-
ble strand. For selected varia-
tions, pathogenicity was evalu-
ated based on in silico predic-
tors and only variations showing
great impact were retained. Fi-
nally, variations were validated
in family members with Sanger
sequencing.
i.e. base-call errors in the sequenced reads that are common in high-throughout
sequencing technologies. Variations were filtered out if occurring in more then 3%
of samples.
SNVs/INDELs have been filtered using a specific algorithm outlined in Figure
3.1. The first step was to remove variations leading to synonymous amino acids
substitutions or if called in off-target regions. In order to exclude polymorphisms,
we also removed all variations with MAF<0.01 based on public databases as NCBI
dbSNP build138, 1000 Genomes Project, Exome Sequencing Project (ESP) Exome
Variant Server, Exome Aggregation Consortium (ExAC). After that, systematic
errors were identified and discarded thanks to a frequency check in our internal
database. For possible de novo variations, additional filters have been applied,
being this category more susceptible for false positive calls. We ensured that the
frequency of the alternative alleles was between 0.4 and 0.6 and that were never
reported as a polymorphism. Moreover, we retained only variations called on both
strands.
In order to specifically identify the putative pathogenic mutation, we performed
a filter designed to select those variants segregating in the family in accordance
to dominant, recessive and X-linked patterns of transmission. According to the
information obtained on the family history, ID was reported as sporadic in all cases
(not recurrent in the pedigree), thus dominant model was tested to identify de novo
mutations. After that, we manually investigated the raw sequence reads for all the
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candidate pathogenic variants using the Integrative Genomics Viewer (IGV) [20] to
exclude likely false positive calls due to read misalignment.
The impact of selected missense mutations on the protein structure was assessed
using three in silico predictor tools, namely, Polyphen-2 [21], MutationTaster [22],
and SIFT [23]. Moreover, evolutionary conservation of nucleotides across species
was evaluated using GERP [30] and CCAD algorithm [32]. Indeed, we expect
pathogenetic variants to be phylogenetically conserved given the sever impact of
ID phenotype. Finally, the most likely identified disease-causing SNVs/INDELs
were analysed by direct Sanger sequencing in probands and their parents, to both
exclude false positive SNVs calling and to perform the segregation analysis within
the family.
We also investigated the presence of CNVs with the use of CoNIFER (COpy
Number Inference From Exome Reads), a software for the detection of deletions
and duplications on exome sequencing data [24]. Results of the CNVs analysis were
then evaluated for the segregation in the families according to the three patterns
of inheritance.
3.3 Discovery of novel candidate mutations
Globally, for the 6 analysed subjects, the percentage of reads mapped in target was
on average 94.79% and the proportion of targeted basis covered at 20x or greater
was on average 82.29% (Table 3.2).
In probands 12-781 and 11-965 at total of 45482 and 45762 SNVs/INDELs
have been annotated respectively. After the application of our custom bioinfor-
matic pipeline, variants have been selected according to three different patterns
on inheritance: de novo, X- linked, and recessive (Figure 3.1). Under the de novo
model 34 variations were identified but only 3 of them resulted as deleterious by
the predictors. However, Sanger sequencing did not validate the mutations in the
probands thus considered false positives. Considering the recessive model, 8 vari-
ants were selected but none of them were predicted as pathogenetic. The X-linked
pattern showed 41 variants and 3 of them revealed high pathogenicity scores (Ta-
ble 3.3). All the 3 X-linked mutations were validated with Sanger sequencing and
resulted as segregating in the families.
In proband 12-781, an X-linked frameshift mutation (NM_001193466, exon8,
c.2078_2079insA, p.P693fs) was identified inGPR64 (or ADGRG2) gene, a member
of the G protein-coupled receptor family. It was originally described as expressed
in the epididymis and studied for its potential role in male fertility. More recently
it was found to be up-regulated in a number of carcinomas, including breast cancer.
GPR64 has never been implicated in ID or other neurodevelopment disorders and
the functional studies carried out in the mouse revealed that the gene expression
was restricted to testis [31]. Although we could not exclude that this mutation is
involved in the aetiology of ID, given the very few studies conducted on the function
of the gene and the information available, we consider unlikely a pathogenetic role
for this mutation.
Two X-linked variations were found in proband 11-965. One is a missense mu-
tation on CLCN4 (NM_001256944, exon10, c.G1909A, p.G637R), a member of the
family of voltage-dependent chloride channel genes. The affected brother was also
evaluated by Sanger sequencing and he was found to share the same hemizygous
variant. CLCN4 encodes the electrogenic chloride/proton exchanger ClC-4 and
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Family Subject ID On Target(%) 20x Coverage(%) SNVs INDELs
T1 12-781 94.19 84.73 43506 1976
T1 12-779 95.03 85.53 43370 2059
T1 12-780 95.91 87.75 44848 2145
T2 11-965 94.92 86.50 43748 2014
T2 13-1536 94.32 85.54 43579 1995
T2 13-1537 94.36 87.68 43909 2051
Table 3.2: WES data statistics. per-subject summary statistics are reported (ID-
patients highlighted in grey): proportion of read mapped on the target region (On Tar-
get(%)), proportion of target region covered at 20x or greater (20x Coverage(%)), number
of called single nucleotide variations (SNVs), number of called insertions/deletions (IN-
DELs).
despite little is known about the physiological role of the protein, it captured our
attention since other members of CLC family are required for normal brain function.
In 2013, Veeramah et al. [33] found a de novo non-synonymous change in CLCN4 in
a patient with refractory complex partial seizure, severe developmental delay with
cognitive impairment, microcephaly, hypotonia. They performed in vitro analyses
using cell-based assays revealing a great impact of CLCN4 mutation on the ion
transport by the ClC-4 exchanger. Moreover, in a very recent study conducted by
Hu et al. [34] where a massive X chromosome sequencing has been applied for more
then 400 ID-patients, CLCN4 has been specifically associated to ID. Missense vari-
ants were discovered in 5 unrelated families where affected males showed variable
degree of ID (ranging from mild to severe) and also intra-familiar variability in the
clinical features that included epilepsy, dysmorphic face, scoliosis and strabismus;
in one case the ID was non-syndromic. In the study, primary neurons derived in
the mouse from Clcn4 knock-out in mice were analysed and showed a significant
effect on neuronal differentiation. Moreover, in order to demonstrate the effects of
mutation, authors performed analyses on Xenopus laevis oocytes and showed that
detected mutations alter the kinetics of activation and impair the function of the
ClC-4 protein.
Another X-linked missense mutation was found in proband 11-965 in gene
ALG13 (NM_001099922, exon23, c.C2672T, p.S891F). Again, the variation was
detected also in the affected brother. ALG13 encodes a protein that interacts with
glycosylation 14 homolog to form a glycosyltransferase complex that functions dur-
ing protein asparagine N-glycosylation. A de novo missense mutation of ALG13
has been previously reported in one child with congenital disorders of glycosylation
(CDG) who died at the age of 1 year [35]. The patient showed refractory epilepsy
with intractable seizures, microcephaly, hepatomegaly, edema of the extremities,
recurrent infections and increased bleeding tendency and died at 1 year. Interest-
ingly, more recently Bissar-Tadmouri N. et al. [36] carried out a study on an Arab
family with five unaffected female siblings and four male siblings with mild to mod-
erate nonsyndromic intellectual disability as the only clinical feature. The family
was analysed with WES approach and the only variation survived to filtering and
validation was a novel missense variant in the ALG13 gene. Given the previous
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finding for ALG13 gene, authors conjectured a pathogenetic role for the discovered
variation.
CNVs examination highlighted deletions and duplications that were already
detected in the analysis of SNP array data. Variations were evaluated at the time
and resulted not implicated in the disease.
Overall, this study led to the discover of 3 X-linked variations in NSynd-ID pa-
tients and two of them appeared as good candidates for having a causative role. In
family F1 a single variant was detected but its implication in ID was considered im-
probable since the affected gene GPR64 is involved in male fertility. Possibly a more
accurate examination of low-coverage regions that could hide additional variations
is required. In family F2 two potentially causative mutations were discovered. The
first mutation affects CLCN4 that very recently was demonstrated to have an effect
on neuronal differentiation and cause ID in 5 unrelated families with variable ID
severity and clinical features, including epilepsy and a case of NSynd-ID. Reported
phenotype variability and the occurrence of epilepsy is consistent with the mani-
fested disease in family F2. In the same family we also found a missense mutation
in ALG13 gene, that was recently associated with X-linked NSyn-ID. In the first
mutation reported for ALG13 by Timal et al. [35], the patient showed a severely
reduced GlcNAc-transferase enzyme activity and thus diagnosed a congenital disor-
ders of glycosylation type I, a recessive neurometabolic disease characterised by an
enormous heterogeneity in clinical symptoms. We therefore believe that the dele-
terious effect of the mutation on the proteine could be demonstrated by measuring
GlcNAc-transferase enzyme activity in the two affected brothers. Unfortunately, at
the stage of this study DNA was the only available sample. Therefore, additional
investigations will be perform to clarify the cause of the disease, primarily the anal-
ysis GlcNAc-transferase enzyme in the two affected boys and functional studies on
the impact of candidate mutation in CLCN4 chanel.
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Chapter 4
Severe cognitive impairment
is associated with increased
Runs of Homozygosity in
Intellectual Disability
This chapter describes a study on the role of Runs of Homozygosity on the cognitive
deficit in ID patients, that has been published in Genetics in Medicine as Gandin I.
et al “Excess of runs of homozygosity is associated with severe cognitive impairment
in intellectual disability.” Genet Med. 2015 May;17(5):396-9. Contributors for this
work are reported at the end of the chapter.
4.1 ROH and inbreeding
The harmful effect of inbreeding is well-known by geneticists and several investiga-
tions have reported cases of neurodevelopment disorders in consanguineous families
caused by recessive variants. Sons of consanguineous couples have an increased
probability to be affected by a recessive pathologies due to identity-by-descent mu-
tations, and this predisposition is inversely correlated with the distance from the
common ancestor. However, only recently the attention has been directed towards
the role of more ancestral inbreeding, which is difficult to be detected from the
pedigree information and has a more subtle effect.
The widespread of high-density SNP-array in the last years has made possible
the study of Runs of Homozygosity (ROHs), long genomic stretches of homozy-
gosity inherited from the same ancestor, which were shown to be extremely useful
to capture distant parental relatedness. In this scenario, ROHs have become a
powerful tool for investigating the role of inbreeding on a large scale in outbred
populations. Although first noted in fitness-related phenotypes, recently studies
identified the amount and the size of Runs of Homozygosity as an important player
in neurological disorders, even if the way through which homozygosity contributes
in the aetiology of the disease is still unclear.
A possible interpretation is that ROHs contain specific loci harboring reces-
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sive mutations that could cause the disease. Under the recessive model of inher-
itance, stretches of homozygosity are the first candidate regions for finding the
pathogenetic mutations (homozygosity mapping). Several studies have made use of
the homozygosity mapping for the identification of variants causing ID in consan-
guineous families, leading to the discovery of a large number of autosomal ID-genes
[42, 43, 44, 12]. However, despite recessive inheritance plays an important role in
ID, ancestral inbreeding has received little attention in the context of ID.
Another possibility is that, like CNVs, some ROH loci can have an effect similar
to contiguous-gene defects. Instead of a single variant conferring disease susceptibil-
ity, there could be a cumulative or interactive effects of contiguous variants within
a homozygous region. The cumulative effect of multiple recessive variants could
play an important role in the aetiology of several neurological diseases, as excess
of ROHs has been identified as a risk factor for Parkinson disease [37], Alzheimer
disease [38], schizophrenia [39], but also speech delay and autism [40] [41].
To shed more light on the possible role of inbreeding on ID, we have set out
a homozygosity study on affected individuals with two principal purposes: 1) test
the extent of homozygosity as risk factor for carrying syndromic features and 2)
investigate the effect of homozygosity on the degree of ID.
4.2 A Runs of Homozygosity study on ID
The study included a cohort of 668 (266 female and 402 males) affected children.
We were able to collect IQ information only for 368 subjects, thus excluding the
remaining individuals from all subsequent analysis. Individuals were then divided
into non-severe ID cases (NSev-ID) for IQ ranging from 35 to 75, and severe ID
cases (Sev-ID) for IQ below 35.
Samples were genotyped using 4 SNP-array platforms: Illumina HumanCyto-
SNP-12v1, HumanCNV370v1, HumanOmniExpress-12v1 and Affymetrix Genome-
Wide Human SNP 6.0, depending on the Health Care Unit providing the samples.
Standard genotyping quality control was performed removing low quality markers
and samples.
To avoid ancestry bias we performed Principal Component Analysis (PCA)
and removed outlier individuals. After this step we proceeded with the detection of
ROHs using the analysis toolset PLINK [45]. We searched for continuous stretches
of at least 100 homozygous autosomal markers and a minimal length of 1Mb. We
chose 1Mb as minimal ROH length since sparser arrays (HumanCytoSNP-12v1
and HumanCNV370v1) are not able to identify shorter stretches. Individuals with
ROHs summing up more than 6.25% of the whole genome were excluded since they
are typical of descendants of close consanguineous marriages [39]. Moreover, in
order to identify possible deletions that will be misclassified as ROHs, we performed
CNV detection analysis using PennCNV [19].
For each subject we considered: 1) the total amount of homozygosity (KB),
which is the total Kb spanned by all ROHs, and 2) the mean length of ROH seg-
ments (KBAVG). To overcome differences in ROH distribution due to the different
array densities, we chose to perform a logistic regression in each dataset and then
combine the results in a meta-analysis using a standard inverse variance method,
in which the contribution of each dataset is weighted and correlated with its size.
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4.3 The effect of ROHs on ID severity
After QC, 19 individual were excluded from genotyped samples, and other 37 were
removed because identified as outliers. Moreover, we detected a total of 32 deletions
and the corresponding genomic regions have been excluded from further analysis.
At the end of these steps, we obtained a clean study sample of 612 individuals. As
expected, the distribution of KB and KBAVG differed between the 4 arrays (Table
4.1).
As a first step, we tested the effect of ROHs on the presence of syndromic
features in individuals with ID. Syndromic conditions are more common in very
close inbreeding and although one mutation can be the cause of Syn-ID, different
features may be due to multiple recessive homozygous mutations in different genes.
We investigated the correlation between homozygosity and complexity of phenotype
in ID cases. We regressed the syndromic/non-syndromic status on KB and KBAVG
for 612 individuals (187 NSyn-ID and 425 Syn-ID) and no association was detected
for KB (ODD=1.02, CI=[0.88,1.20], p=7.5x10-1), neither for KBAVG (ODD=0.99,
CI=[0.94,1.04], p=7.1x10-1).
Based on our analysis, ROHs are not associated with the complexity of the phe-
notype (malformations, seizure, micro/macrocephaly, etc.). A possible explanation
is that in our cohorts the majority of syndromic cases are not the result of multiple
Dataset n SNPs ROH Statistics
Min Q1 Median Mean Q3 Max
TOTAL HOMOZYGOSITY (KB)
Affymetrix 700767 7502 27860 33220 34650 38960 77480
Human
OmniExpress 626132 9392 23290 28730 30950 34350 151500
Human
CNV370 291981 2322 6818 10810 12450 14410 61490
Human Cyto 242657 3858 9994 13040 14810 17000 96130
MEAN LENGTH (KBAVG)
Affymetrix 700767 1209 1209 1411 1480 1505 3099
Human
OmniExpress 626132 1174 1339 1406 1489 1513 5410
Human
CNV370 291981 1161 1477 1638 1845 1963 5331
Human Cyto 242657 1133 1420 1563 1703 1824 4370
Table 4.1: Detailed summary statistics for global homozygosity (KB) and mean
length of ROH stretches (KBAVG) (source: Gandin et al. 2015). Total amount
of homozygosity and the ROH size depend on the number of SNPs included in the array,
which is reported in the second column of the table. The lower KBAVG values for denser
arrays highlights that they are able to detect a greater number of short ROHs, entailing
also a higher score for KB compared to the sparser arrays.
35
Figure 4.1: Single dataset
and combined analysis
for global homozygosity
(A) and mean length
of ROH stretches (B)
(source: Gandin et al.
2015). In (A) we con-
sidered an increase of 10
Mb in KB, while in (B)
the increase in KBAVG was
set to 100 Kb. For each
analysis we reported the
number of individuals (n),
the estimated changes in
odds (OR) and the 95%
confidence intervals (95%-
CI). On the right side, we
reported the meta-analysis
forest plots: the box size
in the graph is proportional
to the contribution of each
dataset.
gene defects but instead single-gene ID syndromes.
The second part of the study was focused on the degree of ID (294 NSev-ID
and 74 Sev-ID). We found significantly larger homozygous stretches in Sev-ID com-
pared to NSev-ID case, together with an increased amount of global homozygosity,
and this despite the lower number of individuals compared to the previous analy-
sis. In Figure 4.1 we reported the odds for severe status and the 95% confidence
interval from the single logistic regressions and the meta-analysis. Notably, for
every 10 Mb increase in total homozygosity the odds for a severe status are in-
creased by 12% (ODD=1.12, CI=[1.01, 1.24], p=3.0x10-2). Moreover, there is a
strong association between KBAVG and the ID degree (ODD=1.08, CI=[1.02,1.14],
p=7.1x10-3). This means that for every 100kb increase in KBAVG the odds for
Sev-ID status are increased by 8%. To check the presence of confounder factors,
several models were tested including sex, first 3 principal components for possi-
ble population stratification, sample origin and Syn-ID/NSyn-ID status: statistical
significance for KBAVG was obtained for all the tests.
We detected a significant association with both total quantity and mean length
of ROHs with the degree of ID. Not surprisingly, these results are very similar to the
effect of homozygosity on ID in simplex autism [41]. The stronger effect of length
with respect to total amount of ROHs can be explained with two mechanisms. On
one side we have to face with an instrumental limitation: we could not analyse
ROH shorter than 1Mb due to the presence of too sparse arrays. Since we are
missing shorter stretches, what is driving the association are long ROHs just because
they are easily detected. Moreover, it is possible that longer ROHs, which arise
from closer inbreeding, could have actually a greater effect according to Szpiech
[46], which reported an enrichment of deleterious variants in long ROHs in healthy
individuals. Similarly, long stretches of homozygosity may contain more likely
damaging variants arising from close inbreeding, which have not yet been purged
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by selection. Those variants may have an important role in ID modulation.
Further investigation would require testing our findings in a larger cohort em-
ploying whole genome sequencing analysis, in order to both obtain a better estimate
of ROHs extent (accounting also for shorter stretches) and try to identify which
genes are mainly involved in ID degree modulation. Probably, the most important
consequence of this study is that, despite the heterogeneity of ID causes in our
cohorts (CNV, INDELs, single-nucleotide-variations), the distribution of homozy-
gosity seems to have an effective impact in determining the severity of impairment.
This is not surprising, since cognitive ability is a very complex trait and its total
variability is unlikely determined by a single pathogenic mutation. Other environ-
mental and genetic factors modulate the phenotype and one of the most important
seems to be accounted by ROHs.
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Chapter 5
Y chromosome and General
cognitive function
In this chapter we present the design of an association study for Y chromosome
to analyse the general cognitive function. Setting up and preliminary results of
the analysis represent the first stage in the creation of the Ygen consortium [47].
Contributors for this work are reported at the end of the chapter.
5.1 Possible role of Y chromosome on sexual di-
morphism in diseases
Intellectual disability has a significantly higher prevalence in males compared to
females. X chromosome has been proved to play a fundamental role in the aetiology
of ID, given the presence of a large number of gene expressed in the brain and
several ID-genes identified in linkage association studies. However, the cause of
male bias still needs to be clarified. The proportion of explained X-linked cases has
been usually around 10-12% but this proportion is still far from the 40% excess
of the disease observed in males, which is even higher if considering mild forms of
ID occurring around 1.9-fold more likely in boys compared to girls [4]. Therefore,
other factors are believed to increase the susceptibility in males. A new investigation
field regards the effects played by hormonal mechanisms. It has been hypothesized
that sex hormones in females could have a neuroprotective action. Moreover, the
exposure of fetal testosterone has been proved to affect the brain development in
animal models and also behaviour in cognitive development in children. Those
results are currently investigated especially for male bias in autism [48].
There are many complex diseases having a large impact on public health that
are sexually dimorphic and specifically more prevalent in males. Most common
examples are the broad range of cardiovascular diseases and type 2 diabetes. An-
other important category are neurological and neuropsychiatric conditions in which
the prevalence and symptomatology differ significantly between males and females.
Strong male bias is observed for autism, attention-deficit hyperactivity disorder
(ADHD), Tourette’s syndrome, schizophrenia, Parkinson’s disease. Very little is
known about the underlying genetic architecture of these differences and new stud-
ies are trying to explore the role of previously overlooked genetic players, like the
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Y chromosome.
The fundamental biological role of the Y chromosome is to impart male charac-
teristics and it is carried only by men. However, it totals about 25 Mb of sequence-
able DNA containing 27 genes or gene families that were entirely neglected in the
search for the determinants of common complex disease. Thus their role in still
largely unknown. A recent study in more then 3200 men using few Y chromosome
markers discovered that haplogroup I conferred a 56% higher risk of coronary artery
disease [49], demonstrating the importance of investigating this genomic region.
In this context, the laboratory of Dr. Wilson at the University of Edinburgh
(UK) has recently formed a consortium aimed to investigate the role of Y chromo-
some on complex traits in a large number of genetic cohorts [47]. In the project
more than 30 diverse traits of public health or evolutionary interest are considered,
including anthropometric measures, haematological counts, cardiovascular risk fac-
tors, metabolic markers, inflammatory response and fertility. Notably, the study
considers also the general cognitive function, which is a global score for fluid cog-
nitive abilities [50]. Giving the extreme interest of this topic for neurodevelopment
disorders and the innovative nature of the study, a fruitful collaboration has been
established with Wilson’s lab and we had the possibility to actively contribute in
the design of the study and its realisation, with a primary focus on outcomes related
to cognitive function trait.
The hypothesis of a possible involvement of Y chromosome in ID is controversial.
While there are recent studies revealing an increased expression of Y-linked genes
in autism and ADHD disorders [51], up to now there is no evidence for similar
results in ID. Recent reviews seem to support the intervention on Y chromosome
for neurological disorders in general [52], mainly based on animal studies in which
several Y-linked genes were found to be expressed in the SRY region, possibly
having a regulatory role. On the other side, in literature there is no trace of ID-
affected families showing a Y-linked pattern of inheritance, thus making unlikely Y
chromosome variations having a pathogenetic role. However, we consider extremely
interesting to investigate a possible influence of the Y chromosome on the cognitive
function, which could be reflected, in case of ID, in a modulation of the cognitive
impairment degree despite not being the cause of the disease.
Since this project represents the first Y chromosome association study on large
scale, the first part of the work has been focused on the research of the methodology
to use, which have been tested on 9 cohorts, providing preliminary results. We
therefore present here the pipeline that has been developed and the preliminary
association outcomes for general cognitive function, which has been measured in 5
of the cohorts.
5.2 Association study on the Y Chromosome
We considered 9 cross-sectional men-cohorts formed by healthy individuals ( see
Table 5.1).
General cognitive function has been calculated for 5 cohorts (see Table 5.1) as
in Davies et al. [50]. Subjects were administered from 3 to 5 tests aimed to measure
different cognitive domain as memory, reasoning, processing speed, spatial ability.
A principal component analysis was carried out on the different cognitive scores
and the measure of general cognitive function was obtained as the resulting first
unrotated principal component. In this way, general cognitive function represented
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Name Label Country n Reference
EGCUT Study EGCUT Estonia 2176 Nelis et al. 2009
AGES Reykjavik AGES Iceland 2216 Harris TB et al. 2007
Orkney Complex
Disease Study ORC
Scotland,
UK 320 McQuillan et al. 2008
Generation
Scotland GS
Scotland,
UK 3490 Smith BH et al. 2012
Lothian Birth
Cohort 1921,1936 LBC
Scotland,
UK 683 Deary IJ et al. 2007
INGI-Val Borbera VB Italy 679 Colonna V et al. 2013
INGI-Carlantino CARL Italy 168 Esko T et al. 2013
Korcula KOR Croatia 273 Polasek O et al. 2009
Silk Road SR Central Asia 148 Mezzavilla M et al. 2014
Table 5.1: Cohorts included in the study. For each cohort, name, short name, origin,
number of males (n) and reference are reported. The total sample size is 10153. General
cognition function was measured only in the 5 cohorts highlighted in grey (EGCUT, ORC,
GS, LBC, KOR), while education attainment was obtained for all cohorts.
the variance that crosses the different fluid cognitive functions. We also considered
educational attainment has been measured in all cohorts as US years of school [53].
We analysed SNP-array data genotyped with the Illumina ExomeChip platform,
a custom-designed chip widely used in the last years since its affordable cost. The
Y chromosome part of the chip contains markers specifically designed to represent
the Y chromosome variability in world-wide populations. Based on preliminary
examinations on the quality of markers, 69 SNPs of the SRY region have been
selected for the analysis, which are able to uniquely identify 65 Y chromosome
haplogroups. Phylogenetic tree and hapogroup definitions are reported in Figure
5.1.
For each cohort, following a standard control on marker and sample quality,
selected SNPs were used to estimate the haplogroup which each individual be-
longs to. This step was essential for the successive inference of missing genotypes.
Haplogroups were defined in terms of SNP configuration following the hierarchi-
cal structure reported in the phylogenetic tree (Figure 5.1). For each individual,
his genotypes and the haplogroup definitions were compared, then the best fitting
haplogroup was selected. If the best-fitting haplogroup was not unique (possibly be-
cause some missing/mismatching SNP, leading to an ambiguous assignment), then
the haplogroup was considered as undetermined. If the best-fitting haplogroup did
not match at least 97% of the SNPs or there were more than one mismatching SNP,
the haplogroup was set undetermined as well.
After haplogroups have been assigned, we were also able to infer the genotypes
of 12 SNPs that were not included in the ExomeChip but known to lie in our phylo-
genetic tree. Once the haplogroup was known, we could infer with certainty a SNP
lying upstream in the genealogical tree, even if it was not genotyped. This tech-
nique was also used to infer missing calls among the genotyped SNPs and finally
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Figure 5.1: Phylogentic tree of the 69 SNPs for the identification of 65 hap-
logroups. In the tree, labels on the branches represent the markers that are named
according to the traditional nomenclature for the Y chromosome. Final leaves labels
represent haplogroups. Markers in bold are genotyped SNPs, while not bolded stand for
imputed SNPs that could be inferred after the haplogroup assignment for subjects. Labels
with p prefix indicate para-SNPs, which are dummy tag-SNPs for those haplogroups that
are not identified by a single SNP.
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also to infer 32 of what we call para-SNPs (markers with p prefix in Figure 5.1)
that can be thought of as tag-SNPs for paraphyletic haplogroups (see Appendix A
for a detailed description). After this step, we obtained of 113 Y chromosome SNPs
dataset and fully exploit the Y data available on the Illumina ExomeChip. Each
of these SNPs represents many further SNPs which are phylogenetically equivalent.
Very few studies have been carried out on Y Chromosome and complex traits,
and most of them used an haplogroup-based approach. This means that samples
are first divided according to their haplogroups and then association is done across
the categories, comparing one group versus all the others. Such approach was
hardly adaptable in our study. We expect to be able to capture a large number
of haplogroups thus the inter-group comparison would have led to many tests.
Moreover, the high-resolution in haplogroup estimation will likely result in several
sub-groups with small number of individuals that are too few to be analysed as a
single category but that can be grouped together to form a more substantial group.
For these reasons we opted for a single-SNP approach in the style of standard
Genome-Wide Association Studies.
Y chromosome variants (and haplogroups) are characterised by high geograph-
ical specificity, which is mostly due to evolutionary mechanisms (the low effective
population size means the Y chromosome is highly susceptible to genetic drift) and
sociological reasons (a predominance of patrilocal societies - where men tend to
stay in one place over generations, e.g. to inherit land). For this reason the first 10
Principal Components and a genomic relationship matrix (for related populations)
were calculated to assist in controlling for cryptic structure across populations.
In addition to pc1-pc10, where a cohort is aware of other covariates (e.g. sam-
pling centre) these are included. For all the analyses, we first fitted covariates in
a linear regression model and then association was performed over the residuals
with the PLINK function --assoc for quantitative traits. For studies with related
populations the mixed model was also calculated. Using GenABEL’s polygenic()
function, we first calculated a mixed model including the kinship matrix as a random
(polygenic) effect, then we performed association over the environment-corrected
residuals with PLINK.
A standard inverse-variance meta-analysis has been applied to single-cohort
results to obtain a global estimate of the association in which only SNPs hav-
ing minor allele count 10 have been considered. Significance level was set to
0:05/113 = 0:0004.
Most of the operations listed above, including haplogroup assignments, SNP
imputation, association, have been implemented in a collection Unix and R scripts.
5.3 Need for higher Y chromosome’s genetic vari-
ability
Haplogroup assignment was successfully performed in more the 95% of samples in
the majority of the cohorts. Only in AGES and CARL the proportion of individ-
uals with determined haplogroup was less then 95% (respectively 92% and 80%)
due to the presence of few missing SNPs. Therefore, in those cohorts SNP impu-
tation was not performed and the analysis was carried out only on the genotyped
markers. The high overall scores and the correspondence between expected and ob-
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Figure 5.2: Frequencies of estimated haplogroups. For each cohort the haplogroups
distribution is represented. Interestingly, there are some groups that represent almost half
of the cohort, like N1c-Tat in EGCUT and I2-P37 in KOR, but almost completely absent
in other populations. As expected, Scottish populations show a very similar frequencies
pattern.
served haplogroup frequencies demonstrated our algorithm as an accurate method
for haplogroup assignment. Indeed, as reported in Figure 5.2, in the Estonian co-
hort EGCUT the group that accounts for almost half of the cohort is N1c-Tat,
which is a very common haplogroup in the Baltic region [54]. Scottish cohorts
(ORC, GS, LBC) present very similar frequencies. Moreover, in Croatian cohort
KOR the most frequent group is I2-P37, which is a sub-group of the very common
I-M170 group in Croatian islands [55]. The most variegated is the Silk Road cohort
(SR), being a mixture of several populations from the Central Asia.
In those cohorts where haplogroups have been assigned in at least 95% of the
dataset, 44 SNPs were imputed, giving a 113 SNPs dataset that have been used
in the single-SNP analysis. We did not find evidence for an association between Y
chromosome SNPs and general cognitive function, although the underlying major
problem is possibly the lack of power in the analysis.
A global representation of association result for general cognition is reported in
Figure 5.3. Here, SNPs are coloured according to the estimated effect, as reported
in the legend. It appears clear that none of the SNPs showed a significant effect.
Only M253 and S142 have arisen with a very weak nominal significance. Details
of the meta-analysis for those SNPs are reported in the forest plot in Appendix
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Figure 5.3: Results of the association study for general cognition. Results are
graphically represented on the phylogenetic tree. Numbers near haplogroup labels rep-
resent the number of samples in each group. Each SNP label is coloured based on the
association outcome: pink if the estimated effect is positive, green if negative. Moreover,
the intensity of the colour is proportional to the significance level, as reported in the leg-
end. SNPs in grey were not tested because too low minor allele count. No signal has been
observed, only M253 and S142 show a light colouring.
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B. An interesting fact emerging from the examination of the tree in Figure 5.3
is the large number of grey labels. They represent SNPs that were discarded in
the meta-analysis because having minor allele count less then 10 in all cohorts.
Notably, 76 out of the 144 SNPs appear to be very rare in our cohorts, despite
the considerable global number of samples (n=6799). This fact can be considered
a direct consequence of the presence of very common haplogroups (see Figure 5.2)
in some of the cohorts that indicate small Y chromosome’s variability with respect
to our selection of SNPs. Very large groups (like N1c-Tat in EGCUT, R1b-127
in Scottish cohorts, I2-P37 in KOR) are actually subdivided in several sub-groups
defined by some specific SNPs that were not included in the ExomeChip and thus
impossible to detect by our algorithm. For the same reason, it should be noted
that the global effect of SNPs calculated in the meta-analysis is obtained with the
contribution of only a subset of the cohorts. Indeed, most of the analysed SNPs
are polymorphic in some cohorts and monomorphic in others. This fact decreases
even further the power of the study.
A recent genome-wide association study focused on the general cognition found
an overlap between SNPs associated with the phenotype of interest and the educa-
tional attainment [50]. We therefore analysed also educational attainment coded as
US years of school attended, that was measured in all cohorts. The outcomes of the
two traits have been compared. Results of the association for education attainment
are represented in Figure 5.4. The strongest signal has been found for SNP M145
(beta=0.37, SE=0.12, P=0.0025), together with pE-M215 and P143 (see Appendix
B) that are highly correlated with M145 due to the strong linkage disequilibrium.
Despite macro-group E was represented in the general cognition analysis by 299
samples, it did not show any signal. Moreover, while I1 brach seems to have a neg-
ative effect on general cognition, although with nominal significance, in the case of
educational attainment the estimated beta is positive, again with nominal signifi-
cance (beta=0.12, SE=0.06, P=0.0315).
The findings of this study led to the conclusion that there is no evidence for a
role of the selected Y chromosome SNPs in determining general cognitive function
in our cohorts. Education attainment has been also examined given the correlation
between the two traits, but no SNPs were found to be associated and outcomes were
not overlapping, even when considering results at the nominal significance level.
We also observed a great proportion of SNPs too rare to be tested in the
association study. The 69 selected SNPs were designed to represent the world-
wide variation of Y chromosome, however for some cohorts they are not able to
provide a haplogroup subdivision with high resolution. It is interesting to note
that for educational attainment the number of analysed cohorts has been increased
(9 cohorts for a total of 10153 subjects) and this has resulted in a lower number of
discarded SNPs (69 SNPs compared to 75 SNPs excluded for general cognition).
A problematic aspect of this study seems to be the reduce Y chromosome vari-
ability provided by our cohorts. However, findings here reported represent only the
preliminary results of an international consortium that is expected to receive the
contribution of a large number of groups, providing cohorts from almost all world
populations [47]. The Illumine ExomeChip has been largely used in the last years
since its affordable costs and the number of genetic cohorts that have been geno-
typed using this platform is now remarkable. Moreover, the collaboration will be
facilitated by proving a collection of scripts for the execution of the analyses in the
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Figure 5.4: Results of the association study for educational attainment. Given the
correlation usually observed with general cognition, also education attainment has been
analysed. The strongest signal has been found in the E branch that, although represented
in general cognition cohorts, did not show association in the previous analysis. SNP M253
has opposite effect compared to the general cognition analysis.
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single cohorts, making the contribution of the groups simpler and faster. Thus the
achievement of the required power in terms of sample size and Y chromosome vari-
ability in the next future appears plausible. The inclusion of cohorts with different
ancestries as Africans, South Americans, East Asians, South Asians, will increase
the chances of testing a large proportion of the SNPs in our selection and the effect
of markers will be easily interpreted in terms of haplogroups, as reported in the
graphical tree-representation. Any finding regards Y chromosome determinants for
the cognitive function could clearly lead to fundamental new insights for the study
of neurological and neuropsychiatric disorders.
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Conclusion
Intellectual Disability is a complex disease and this thesis represent an attempt to
shed more light on its the genetic bases using diverse approaches.
In the first part we have focused on the search of causing mutations in a
Mendelian setting, where the disorder is transmitted according to dominant, re-
cessive or X-linked pattern. Thanks to a pre-screening strategy on the most com-
mon genes for the non-syndromic ID, we have been able to identify novel candiate
mutations for the disease. Some of these variations are located in genes already as-
sociated to the disease, but others have been found in genes only recently implicated
on ID or only hypothesised to be involved.
In the second part of the work, ID have been approached as a more complex
disorder, considering that its phenotype in unlikely determined by a single variant.
We have focused our attention on other genetic factors that, despite not being the
main cause of the disease, can influence the phenotype in patients. We have shown
that excess of homozygosity has an effective impact in determining the severity of
impairment. Such result has led to speculations about a possible cumulative effect of
multiple recessive variants in the modulation of the degree of the impairment. Based
on recent findings for other neurodevelopment disorders, we have also analysed the
possible role of Y chromosome variants in the development of the cognitive function.
Our preliminary results do not show associations but the study will gain more power
adding more cohorts in the next future.
We can conclude that the research on the causing mutations is a fundamental
part in the investigation on ID, since there is a large number of genetic variants with
pathogenetic role that still need to be discovered. At the same time, it is important
to approach ID as polygenic disorder, since cognitive function is the result of the
effect of many genetic factors.
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Appendix A
We describe here the inference of missing SNPs in the association study for the Y
chromosome.
After the estimation of haplogroups for individuals, we were also be able to
infer 12 SNPs and 33 para-SNPs. In Figure A.1 a graphical representation of the
mechanism is reported for zoomed part of the tree. Haplogroup assignment was
performed on the genotyped SNPs (Fig. A.1 (a)).
Since there were 12 SNPs that have not been included in the ExomeChip but
known to lie in our phylogenetic tree (Fig. A.1 (b)), it was possible to infer with
certainty the genotypes for our subjects.
Some of the haplogroup are uniquely identified by single SNPs, like D-M174
which is determined by SNP M174. But there are others, like E-M521, which are
paraphyletic groups and thus not represented by a unique marker. In order to
include in the analysis the possible effects of paraphyletic groups, we defined 33
para-SNPs, that are dummy SNPs which capture a haplotype effect in one binary
variable (Fig. A.1 (c)). These SNPs do not really exist, but they are an efficient way
to capture all the information in the genotypes along with the known genealogical
relationships. These SNPs are assigned dummy positions and alleles (I/O, I=in
O=out), and can be thought as tag-SNPs for the paraphyletic groups.
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Figure A.1: Imputation of Y chromosome SNPs. (a) Genotyped SNPs. (b) Imputed
SNPs. (g) para-SNPs.
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